The expression level of TNPO2 predicted week prognostic power for clinical utility (AUC = 0.546) while the expression levels of SEC16B predicted no significant association with chemotherapy sensitivity of the hub cancers (Figure 7B). This evidence concerns the gene TNPO2 and cancer.